Right then, let’s dive into IDH’s first-quarter numbers. The headline figures are certainly attention-grabbing: a robust 35% surge in revenue to EGP 1.58 billion. But as always with IDH, the real story lies beneath the surface – in the margins, the geographic nuances, and that fascinating normalisation of currency effects. This isn’t just growth; it’s growth with improving efficiency.
Beyond the Headline Numbers: Profitability & The FX Mirage
While revenue soared, a glance at the reported net profit (down 39% to EGP 245 million) might cause a double-take. Don’t be fooled. This is almost entirely down to the absence of last year’s extraordinary FX gains (EGP 301 million in Q1 2024 vs. a more modest EGP 31 million this quarter). As the Egyptian Pound (EGP) and Nigerian Naira stabilised, those windfall gains evaporated. This is a sign of relative currency stability returning, not underlying weakness.
Strip out those volatile FX gains, and the picture transforms dramatically:
- Normalised Net Profit: More than doubled (+114%) to EGP 214 million.
- Normalised Net Profit Margin: Expanded significantly by 5 percentage points to 13.5%.
The core profitability engines are firing much better:
- Gross Profit Margin: Jumped to 39.8% (from 36.6% in Q1 2024) – a 3.3 ppt improvement. This reflects excellent cost control, particularly on raw materials (down to 19.5% of revenue from 21.1%).
- EBITDA Margin: Climbed to a healthy 31.5% (from 28.2%) – another 3.3 ppt gain. This was driven by the gross margin improvement, lower bad debt provisions (thanks to better collections and improving economic conditions), and ongoing SG&A efficiency despite inflation.
- EBITDA Itself: Surged 51% year-on-year to EGP 498 million.
The Operational Engine: Price Power & Strategic Shifts
Volumes (tests and patients) dipped slightly (-1% and -8% respectively), primarily due to Ramadan starting earlier in March 2025 vs. March 2024. However, IDH demonstrated impressive pricing power:
- Revenue per Test: Soared 37% to EGP 185.
- Revenue per Patient: Jumped 46% to EGP 839.
Crucially, the strategic focus on increasing the value extracted per patient visit continues to pay dividends:
- Tests per Patient: Rose to a record 4.5 (from 4.3 in Q1 2024), showcasing the success of loyalty programmes and service bundling.
- Network Expansion: Added a net 54 branches over the last year (mainly in Egypt), taking the total to 641. (Note: Only 1 of 18 Sudan branches is operational).
Geographic Breakdown: Egypt Anchors, Nigeria Turns, Saudi Simmers
Egypt (82.7% of Revenue): The Steady Powerhouse
- Revenue: EGP 1.31 billion (+32% YoY).
- Driver: Strategic price hikes (Revenue per Test +37%) offsetting slight Ramadan-related volume dips.
- Scale: Network reached 600 branches (+54 YoY). House calls contributed a strong 21% of Egyptian revenue.
- Profitability: EBITDA +39% to EGP 444mn; Margin up to 33.9%.
Jordan (14.8% of Revenue): Volume Surprise
- Revenue (JOD): JOD 3.3mn (+2% YoY).
- Revenue (EGP): EGP 234mn (+42% YoY – translation effect).
- Highlight: Test volumes surged 16% YoY due to a successful promotional campaign, offsetting a slight dip in average revenue per test locally.
- Profitability: Solid EBITDA margin expansion to 26.2%.
Nigeria (1.8% of Revenue): The Turnaround Milestone
- Revenue (NGN): NGN 840mn (+39% YoY).
- Revenue (EGP): EGP 28mn (+78% YoY – translation effect + price hikes).
- The Big News: Turned EBITDA positive in Q1 2025! Reported NGN 65mn EBITDA (8% margin) vs. a NGN 244mn loss last year. This validates the revamped turnaround strategy.
- Challenge: High inflation still pressured volumes (Tests -6%, Patients -13%).
Saudi Arabia (0.7% of Revenue): The Growth Wildcard
- Revenue (SAR): SAR 0.8mn (Up 31% QoQ from Q4 2024).
- Momentum: Test volumes hit 28k in Q1 (up from 2k in Q1 2024!), even with Ramadan impact. Served 5k patients.
- Ownership: IDH now owns 100% (79% directly, 21% via Biolab Jordan) after buying out Izhoor’s stake.
- Outlook: Aggressive marketing and plans for 4 new branches (total 6) signal strong commitment to this high-potential, fragmented market. Losses are narrowing as scale builds.
Sudan: Minimal Contribution
Only 1 of 18 branches remains operational due to the ongoing conflict.
Balance Sheet & Cash: Fortress Strength
IDH remains exceptionally well-capitalised:
- Cash & Financial Assets: EGP 1,662 million (down slightly from YE 2024, but still very substantial).
- Net Cash Position: Strengthened to EGP 385 million (from EGP 227 million at YE 2024). Excluding lease liabilities, net cash is a formidable EGP 1,321 million.
- Interest Bearing Debt: Reduced significantly to EGP 88 million (excl. accrued interest).
Management Outlook: Confident & Ambitious
CEO Dr. Hend El-Sherbini struck a decidedly optimistic tone, citing:
- Improving operating conditions, especially in Egypt (slowing inflation, rate cuts).
- Expectation for volume recovery post-Ramadan.
- Biolab KSA (Saudi) as a pivotal growth driver for 2025.
- Guidance: Full-year 2025 revenue growth anticipated above 30%, with an EBITDA margin “north of 30%”.
The Takeaway: Efficiency Gains Meet Strategic Execution
IDH’s Q1 2025 is a story of impressive execution. They’ve navigated currency normalisation expertly, revealing strong underlying profit growth once the FX noise is stripped away. The core Egyptian business remains a money spinner, Jordan delivered a volume surprise, and the Nigerian turnaround hitting EBITDA positivity is a major, hard-won milestone.
Perhaps most exciting is the quiet, rapid build-out in Saudi Arabia – a market with immense long-term potential where IDH is laying solid foundations. Combine this geographic execution with demonstrable success in boosting margins through cost control and operational efficiencies (raw materials, collections), and you have a company starting 2025 on a very firm footing. The guidance suggests management sees this momentum continuing. One to watch closely.
